The goal of this observational study is to learn about repetitive anaphylactic reactions in food allergic patients and to compare the frequency of repetitive reactions between different elicitors in food allergic patients. The main question it aims to answer are:
• Is there an elicitor specific difference in the occurrence of anaphylactic reactions once the elicitor has been identified and the patient received counselling about its avoidance?
Participants will answer questionnaires via a link they will receive via e-mail at baseline and 3, 6, 12 and 24 months after inclusion in the study.
Eligibility
Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* anaphylactic reaction to peanuts, other legumes, tree nuts, seeds (e.g. sesame seed, sunflower seed), cereals (e.g. wheat, oat) or pseudocereals (e.g. quinoa)
* participation in the European Anaphylaxis Registry (Clinical Trials Identifier: NCT05210543)
* possibility and consent to receive links to the follow-up electronic surveys via e-mail and fill out the questionnaires electronically
Exclusion Criteria:
* if inclusion criteria are fulfilled there are no further exclusion criteria
Primary outcome measure(s)
Frequency of allergic reactions in tree nut and peanut allergic patients within the observation period of the study — 2 years The aim is to identify whether the frequency of allergic reactions after the identification of the elicitor of the initial allergic reaction differs between peanuts and tree nuts
Trial sites (1)
Facility
City
Region
Status
Charité - Universitätsmedizin Berlin
Berlin
State of Berlin
Recruiting
More Charite University, Berlin, Germany trials in Germany
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.